Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference MEDIA RELEASE Strong first...
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation Ad hoc announcement pursuant to art. 53 SIX Swiss...
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio MEDIA RELEASE Afqlir®...
Sandoz reports third-quarter and nine-month 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE...
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position Ad hoc announcement pursuant to art. 53...
Sandoz reports second-quarter sales and half-year 2024 results Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA...
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Ad hoc announcement pursuant to art. 53...
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Ad hoc announcement pursuant to art. 53 SIX Swiss...
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe Ad hoc announcement...
Sandoz reports first quarter 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first...
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG All proposals of Board of...
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Ad hoc announcement pursuant to art...
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering Ad hoc announcement pursuant to...
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines MEDIA RELEASE EUR 50m...
Sandoz reports fourth quarter 2023 sales and full-year 2023 results Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지